A US federal jury awards Apple $250, finding that Masimo's smartwatches infringed Apple Watch design patents; Apple sought statutory minimum damages
Apple Inc. v. Masimo Corp. (D. Del., 22-cv-1377) — Apple Inc. v. Masimo Corp. (D. Del., 22-cv-1378) — Search by Law Firm Search by Topic Search by Company
Context & Ripple Effects
This verdict is one branch of a broader Apple–Masimo IP conflict that included Apple's 2022 allegation that Masimo studied its intellectual property while developing the W1 watch. An earlier trade-secret case ended in a mistrial, leaving multiple legal theories unresolved rather than settling the rivalry.
The nominal award makes the design-patent finding more important as a legal validation than as a financial recovery. Later coverage underscores the dispute's two-sided nature: a separate jury found Apple liable for blood-oxygen patent infringement, with Apple saying it would appeal.
First-order effects
- Apple obtains a jury finding that Masimo's smartwatches infringed Apple Watch design patents, reinforcing its position in this design-focused case.
- Masimo faces an adverse infringement verdict, but the $250 statutory-minimum award limits the immediate monetary impact.
Second-order effects
- The outcome gives both sides another adjudicated result to weigh as their wider patent conflict continues; the later blood-oxygen verdict shows that neither company has a one-directional litigation advantage.
- Wearable-device makers are reminded that product exposure can arise from both outward design and health-feature technology, requiring separate IP risk assessments.
Third-order effects
- If such cross-claims persist, wearable competition is likely to be shaped increasingly by overlapping design and sensor-patent portfolios rather than product differentiation alone.
- The sharply different damages outcomes in the related cases suggest that the economic stakes will depend heavily on the specific IP right and alleged feature, not simply on the presence of infringement litigation.
The trend: The Apple–Masimo dispute is part of a broader trend in which wearables makers use parallel design, trade-secret, and health-sensor patent claims to contest product boundaries.